Last quarter (Q ), Reunion Neuroscience's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q, Reunion Neuroscience's net income was $-6.49M. See Reunion Neuroscience’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Mar 20
Total Revenue	$ 1.62M	-	-	$ 960.89K	$ 1.00K
Cost of Revenue	-	-	-	$ 1.54M	$ 9.40K
Gross Profit	$ 1.62M	-	-	$ -583.43K	$ -8.40K
Operating Expense	$ 21.40M	$ 27.78M	-	$ 18.45M	$ 3.27M
Operating Income	$ -19.78M	$ -27.78M	-	$ -19.03M	$ -3.27M
Net Non Operating Interest Income Expense	$ -311.26K	-	-	$ -252.26K	$ -19.91K
Other Income Expense	$ -18.30M	$ 3.43M	-	$ -3.84M	$ 666.41K
Pretax Income	$ -10.41M	$ -38.10M	-	$ -23.12M	$ -2.63M
Tax Provision	-	-	-	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	$ 8.34M	$ -3.43M	-	-	-
Net Income Common Stockholders	$ -26.88M	$ -48.49M	-	$ -23.12M	$ -2.63M
Basic EPS	$ 0.20	$ -0.04	-	$ -0.70	$ -0.07
Diluted EPS	$ 0.21	$ -0.03	-	$ -0.70	$ -0.07
Basic Average Shares	$ -25.22M	$ -48.49M	-	$ 33.07M	$ 37.99M
Diluted Average Shares	$ -25.22M	$ -48.49M	-	$ 33.07M	$ 37.99M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	$ 897.39K	$ 317.48K
Total Expenses	$ 21.40M	$ 27.78M	-	$ 19.99M	$ 3.28M
Net Income From Continuing And Discontinued Operation	$ -18.64M	$ -48.49M	-	$ -23.12M	$ -2.63M
Normalized Income	$ -10.56M	$ -19.67M	$ -54.69M	$ -19.28M	$ -3.29M
Interest Expense	-	-	-	$ 303.30K	$ 22.56K
EBIT	$ -9.89M	$ -38.10M	$ -53.59M	$ -22.81M	$ -2.61M
EBITDA	$ -3.59M	$ -34.87M	-	$ -21.42M	$ -2.46M

Currency in USD

Reunion Neuroscience Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing